Trial · NCT03269552
Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma
NCT03269552, Phase 2, Terminated, University of Washington; results first posted 2020-01-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma. Trials, record NCT03269552. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03269552
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma
- NCT number
- NCT03269552
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 4 participants, actual
- Lead sponsor
- University of Washington
- Conditions
Marginal Zone Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Marginal Zone Lymphoma, Refractory Waldenstrom Macroglobulinemia, Waldenstrom Macroglobulinemia
- Interventions
- Carfilzomib, Laboratory Biomarker Analysis, Rituximab
- First posted
- 2017-08-31
- Last updated
- 2020-01-18
- Results first posted
- 2020-01-18
- Limitations and caveats
- Early termination due to low accrual leading to small number of subjects analyzed.
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Response Rate | Up to 1 year | Descriptive statistics will be used for baseline characteristics, and responses to treatment. |
| Secondary | Overall Survival | Up to 1 year | Estimated using Kaplan-Meier analysis. |
| Secondary | Time to Best Response | Up to 1 year | Estimated using Kaplan-Meier analysis. |
| Secondary | Time to Progression | Up to 1 year | Estimated using Kaplan-Meier analysis. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Response Rate | Up to 1 year | Participants who were evaluated after cycle 2 day 15 and prior to cycle 3 day 1. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Overall Survival | Up to 1 year | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Time to Best Response | Up to 1 year | Months | MEDIAN | |
| SECONDARY | Time to Progression | Up to 1 year | Months | MEDIAN |
Source ClinicalTrials.gov
Results by group9
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate | Treatment (Carfilzomib, Rituximab) | Complete response | 0 | Participants | |
| Overall Response Rate | Treatment (Carfilzomib, Rituximab) | Very good partial response | 0 | Participants | |
| Overall Response Rate | Treatment (Carfilzomib, Rituximab) | Partial response | 2 | Participants | |
| Overall Response Rate | Treatment (Carfilzomib, Rituximab) | Minor response | 1 | Participants | |
| Overall Response Rate | Treatment (Carfilzomib, Rituximab) | Stable disease | 1 | Participants | |
| Overall Response Rate | Treatment (Carfilzomib, Rituximab) | Progressive disease | 0 | Participants | |
| Overall Survival | Treatment (Carfilzomib, Rituximab) | 4 | Participants | ||
| Time to Best Response | Treatment (Carfilzomib, Rituximab) | 2 | Full Range 0.5 to 3 | Months | |
| Time to Progression | Treatment (Carfilzomib, Rituximab) | 8 | Standard Error 0.05 | Months |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment (Carfilzomib, Rituximab) | 4 | |
| Overall Study | COMPLETED | Treatment (Carfilzomib, Rituximab) | 2 | |
| Overall Study | NOT COMPLETED | Treatment (Carfilzomib, Rituximab) | 2 |
Source ClinicalTrials.gov
Adverse events26
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Treatment (Carfilzomib, Rituximab) | 1 | 4 | 1 |
| other | Constipation | Gastrointestinal disorders | Treatment (Carfilzomib, Rituximab) | 1 | 4 | 1 |
| other | Chills | General disorders | Treatment (Carfilzomib, Rituximab) | 2 | 4 | 3 |
| other | Cough | General disorders | Treatment (Carfilzomib, Rituximab) | 1 | 4 | 1 |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Treatment (Carfilzomib, Rituximab) | 1 | 4 | 1 |
| other | Fatigue | General disorders | Treatment (Carfilzomib, Rituximab) | 2 | 4 | 2 |
| other | Flatulance | Gastrointestinal disorders | Treatment (Carfilzomib, Rituximab) | 2 | 4 | 3 |
| other | Flu Like Symptoms | General disorders | Treatment (Carfilzomib, Rituximab) | 1 | 4 | 1 |
| other | Fluid Retention | General disorders | Treatment (Carfilzomib, Rituximab) | 1 | 4 | 1 |
| other | Warm Sensation | General disorders | Treatment (Carfilzomib, Rituximab) | 1 | 4 | 1 |
1 to 10 of 26Source ClinicalTrials.gov
See all 26 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment (Carfilzomib, Rituximab) | 0 | 4 |
| Total, other adverse events | Treatment (Carfilzomib, Rituximab) | 4 | 4 |
| Total, serious adverse events | Treatment (Carfilzomib, Rituximab) | 1 | 4 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA015704 | Cancer Center Support Grant | LYNCH, THOMAS JAMES | FRED HUTCHINSON CANCER CENTER | NATIONAL CANCER INSTITUTE | 1985 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03269552
GET https://conductscience.org/api/trials/v1/NCT03269552/events?page=2